The combination of the JAK1/2 and TBK1 inhibitor momelotinib with erlotinib did not enhance benefit over historical controls of erlotinib monotherapy in patients with EGFR-mutated NSCLC and did not support enrollment to the randomized dose expansion [2, 33, 34]. This evidence concerns the gene JAK1 and non-small cell lung carcinoma.